In what is being heralded as a breakthrough for cancer research, GW Pharmaceuticals announced on Tuesday positive results from a study using a combination of cannabidiol and tetrahydrocannabinol to treat an aggressive form of brain cancer.
Glioblastoma multiforme, or GBM is a “particularly aggressive brain tumor, with a poor prognosis,” according to the British-based biopharmaceutical company focused on developing proprietary cannabinoid medicine.
RELATED STORY: Can Marijuana Really Cure Cancer? Here’s The Science
According to the study, patients with documented recurrent GBM treated with THC:CBD had an 83 percent one year survival rate compared with 53 percent for patients taking a placebo.
Said Professor Susan Short, principal investigator of the study:
“The findings from this well-designed controlled study suggest that the addition of a combination of THC and CBD to patients on dose-intensive temozolomide produced relevant improvements in survival compared with placebo and this is a good signal of potential efficacy. Moreover,